Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2011
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 09 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Oct 2009 Planned end date (Nov 2009) added as reported by ClinicalTrials.gov.